MESSAGE FROM MANAGEMENT

I am pleased to present Sanofi China’s third Corporate Social Responsibility Report, following the 2013 and 2015 editions. In recent years, healthcare became an even more important topic worldwide. Globally, the United Nations Sustainable Development Goals (SDGs) were officially launched, in which “good health and well-being” have become one of the 17 objectives. In China, the government launched the Healthy China 2030 blueprint, which will definitely speed up the development of the healthcare industry. These achievements will undoubtedly bring new demands and new opportunities to each and every healthcare company.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

The third is commitment. Our commitment to “in China, for China” has remained unchanged since we entered China in 1982. Dedicated to becoming an excellent Chinese corporate citizen, we uphold the highest ethical standards and fulfill our responsibilities to our stakeholders, our communities and the environment. In recent years, we have contributed to humanitarian relief, employee care, energy conservation and emission reduction, and environmental protection.

Whether it is innovation, partnership or our commitment to “in China, for China,” it all boils down to Empowering Life – our sustained mission. As a healthcare company, our first and foremost responsibility is to keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

The third is commitment. Our commitment to “in China, for China” has remained unchanged since we entered China in 1982. Dedicated to becoming an excellent Chinese corporate citizen, we uphold the highest ethical standards and fulfill our responsibilities to our stakeholders, our communities and the environment. In recent years, we have contributed to humanitarian relief, employee care, energy conservation and emission reduction, and environmental protection.

Whether it is innovation, partnership or our commitment to “in China, for China,” it all boils down to Empowering Life – our sustained mission. As a healthcare company, our first and foremost responsibility is to keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

The third is commitment. Our commitment to “in China, for China” has remained unchanged since we entered China in 1982. Dedicated to becoming an excellent Chinese corporate citizen, we uphold the highest ethical standards and fulfill our responsibilities to our stakeholders, our communities and the environment. In recent years, we have contributed to humanitarian relief, employee care, energy conservation and emission reduction, and environmental protection.

Whether it is innovation, partnership or our commitment to “in China, for China,” it all boils down to Empowering Life – our sustained mission. As a healthcare company, our first and foremost responsibility is to keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

The third is commitment. Our commitment to “in China, for China” has remained unchanged since we entered China in 1982. Dedicated to becoming an excellent Chinese corporate citizen, we uphold the highest ethical standards and fulfill our responsibilities to our stakeholders, our communities and the environment. In recent years, we have contributed to humanitarian relief, employee care, energy conservation and emission reduction, and environmental protection.

Whether it is innovation, partnership or our commitment to “in China, for China,” it all boils down to Empowering Life – our sustained mission. As a healthcare company, our first and foremost responsibility is to keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

The third is commitment. Our commitment to “in China, for China” has remained unchanged since we entered China in 1982. Dedicated to becoming an excellent Chinese corporate citizen, we uphold the highest ethical standards and fulfill our responsibilities to our stakeholders, our communities and the environment. In recent years, we have contributed to humanitarian relief, employee care, energy conservation and emission reduction, and environmental protection.

Whether it is innovation, partnership or our commitment to “in China, for China,” it all boils down to Empowering Life – our sustained mission. As a healthcare company, our first and foremost responsibility is to keep being engaged in the healthcare ecosystem. We partner with scientific research institutions, universities, disease associations, peer companies, and a variety of professional platforms through multi-dimensional strategic partnerships. We firmly believe that only by working with partners and integrating the advantages of all parties can we promote healthcare undertakings in China.

This report is our latest CSR response to the needs of Chinese people and the society. As a healthcare company, our first and foremost responsibility is to develop and manufacture innovative drugs and vaccines. As a corporate citizen, we are also aware that we have more social responsibilities beyond offering drugs and vaccines. In Sanofi, we have identified four pillars of Sanofi’s CSR strategy: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with Communities, and Healthy Planet. Aligning with group CSR strategy, our contribution to the Chinese healthcare industry and our CSR practices in China can be summed up in three words.

The first is innovation. Innovation is the cornerstone of Sanofi’s sustainable growth in China and worldwide. Focusing on research and development, we commit to introducing innovative, high-quality products in China. Meanwhile, we are constantly innovating our business model, making new contributions to primary care by going deep into counties and deploying the innovative Healthy Community project. Furthermore, the rapid development of the internet and mobile technology provides us with an opportunity to expand digital programs in what we are expert in.

The second is partnership. To meet the needs of public health in China, we keep being engaged in the healthcare ecosystem. We partner with scientifi...
ABOUT SANOFI

Company Profile

Sanofi is dedicated to supporting people through their health challenges. As a global biopharmaceutical company, Sanofi focuses on human health, prevents illness with vaccines, and provides innovative treatments to fight pain and ease suffering. Sanofi stands by the few who suffer from rare diseases and the millions with long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life.

Our 5 Global Business Units

- Diabetes & Cardiovascular (Sanofi Pasteur)
- Specialty Care (Sanofi Genzyme)
- General Medicines and Emerging Markets
- Consumer Healthcare
- Vaccines (Sanofi Pasteur)

Company Profile

- More than 100,000 employees in the world*
- Present in more than 100 countries
- 33.8 billion euros net sales in 2016*

Note: * The business swap of Merial is not included.

Our 5 Global Business Units

- Diabetes & Cardiovascular
- Specialty Care (Sanofi Genzyme)
- General Medicines and Emerging Markets
- Consumer Healthcare
- Vaccines (Sanofi Pasteur)

R&D

- 4 R&D Hubs based in China, France, Germany and the United States
- 15.3% of sales are invested in R&D.
- The annual R&D investments will increase to 6 billion euros by 2020

- More than 16,000 R&D employees

Sanofi values

- Integrity: Operating with honesty and transparency, ensuring the highest ethical and quality standards
- Respect: Embracing the diversity, different thoughts and needs of employees, customers and communities
- Teamwork: Performing at our best to improve people’s lives, winning together as One Sanofi
- Courage: Daring to innovate, taking ownership and risks, and learning from failure

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary. Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.

Life is a health journey, with its ups and downs, and its challenges. These can be big or small, lifelong or temporary.

Sanofi, a health journey partner. We, at Sanofi, are there beside people in need, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.

Sanofi, Empowering Life.
Sanofi China and its footprints

In 1982, Sanofi became one of the first multinational pharmaceutical companies to open offices in China. Sanofi currently employs about 9,000 people in China and is one of the fastest-growing healthcare companies in the country.

Sanofi is headquartered in Shanghai, with 11 regional branches in Beijing, Tianjin, Shenyang, Jinan, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou, Fuzhou and Urumqi, and three manufacturing facilities in Beijing, Hangzhou and Shenzhen.

Sanofi China employs around 9,000 people*
Present in 1,700+ counties and cities
2,039 billion euros net sales in 2016*  

NOTE: * As Sanofi adjusted its group business and business in China, the manufacturing facility no longer includes Merial Nanchang Animal Healthcare Plant, Merial Nanjing Animal Healthcare Plant and Hangzhou Sanofi-Minsheng Consumer Healthcare Plant. Tangshan Consumer Healthcare Plant has been incorporated into Sanjiu Sanofi (Shenzhen) Consumer Healthcare Ltd.

Vaccines
Sanofi Pasteur is a worldwide leader devoted entirely to human vaccines. With innovative vaccines preventing influenza, pneumococcal disease and pediatric infectious diseases, Sanofi Pasteur contributes to the advancement of disease prevention in China.

Consumer healthcare
In 2010, Sanofi entered the consumer healthcare market in China. In 2016, Sanofi and China Resources Sanjiu signed an agreement to establish a strategic partnership. The partnership encompasses a joint venture focusing primarily on pediatric and gynecological OTC products, as well as a platform for future launches in China of other Sanofi consumer healthcare world-leading brands.
Sanofi became one of the first multinational pharmaceutical companies to open offices in China.

Established the first regional office in Guangzhou.

Sanofi merged with Aventis.

Established the China R&D Center in Shanghai.

Genzyme, the rare disease leader, was integrated into the Sanofi family.

Established the Asia-Pacific R&D Hub in Shanghai.

Sanofi announced investment in a world-class flu vaccine facility in Shenzhen.

Beijing pharmaceutical facility (founded in 1995) increased investment by RMB 545 million.

The new plant of Hangzhou pharmaceutical facility (founded in 1995) began production with an investment of RMB 430 million.

Established a strategic partnership with China Resources Sanjiu in consumer healthcare.


The journey of Sanofi China.
Corporate social responsibility, as an important asset of the company’s strategy, is incorporated into the core values and sustainable development strategy of the company. Sanofi focuses on ethics and transparency, access to healthcare for the underserved, engage with communities, and healthy planet. Sanofi practices corporate social responsibility to achieve common sustainable development of all parties.
MANAGEMENT STRUCTURE

A CSR Cross-functional strategy Committee (CCC) was established for better developing and implementing the group CSR strategy. It is co-chaired by the Chief Medical Officer, the Executive VP Human Resources and the Head of External Affairs, and each member of the Executive Committee. As a policy-maker at Sanofi CSR management, the Committee is responsible for identifying projects or topics that need to be discussed at the Group Executive Committee level. As the coordinating department of CSR execution, the CSR Department is responsible for the implementation of social responsibility.

Under the framework of the group’s CSR management, key issues of social responsibility have been integrated into BU’s, daily production and operation at Sanofi China. As an important part of implementing Sanofi group’s social responsibility strategy and promoting the social responsibility management of Sanofi China, Communication at Sanofi China coordinates local community programs such as Sanofi Hope Volunteer Group, and carry out social responsibility practice and promotion according to the expectation of stakeholders.

Sanofi has always attached importance to the role of material issue identification in social responsibility management and continues the task on the basis of reference to international sustainable development trends and standards and related issues in the pharmaceutical industry. At the same time, Sanofi is committed to building close relationship with stakeholders, meeting their expectations by enhancing listening and communication, and identifying our material issues on a continuous basis.

In 2016, Sanofi identified the material issues of corporate social responsibility, including access to healthcare, business and R&D ethics, patient safety, and economic and environmental footprints through interviews and dialogues with 50 stakeholders from around the world and subsequent validation. The stakeholders also provide advices on how to update Sanofi CSR strategic roadmap, discuss key issues affecting Sanofi, and explore specific actions conducted together with stakeholders. In 2017, Sanofi China further identified and selected the stakeholder groups based on local situation and the characteristics of the healthcare industry, and the material issues were reviewed and revised by the company’s management and external experts.

The material issues of Sanofi China

<table>
<thead>
<tr>
<th>Stakeholders</th>
<th>Issues of concern</th>
<th>How we communicate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government / regulatory agencies</td>
<td>• Business ethics</td>
<td>• Regular visits and exchanges</td>
</tr>
<tr>
<td>• Product quality</td>
<td>• Anti-counterfeit initiatives</td>
<td>• Information disclosure</td>
</tr>
<tr>
<td>• Primary Care</td>
<td>• Pharmaceutical in Environment (PIE)</td>
<td>• Regulatory requirements</td>
</tr>
<tr>
<td>• Waste management</td>
<td>• Stakeholder dialogues</td>
<td></td>
</tr>
<tr>
<td>• Water management, including Pharmaceuticals in the Environment (PIE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Awareness of the impact of climate change on health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients</td>
<td>• Business ethics</td>
<td>• Health promotion</td>
</tr>
<tr>
<td>• Innovation</td>
<td>• Initiate projects</td>
<td></td>
</tr>
<tr>
<td>• Product quality</td>
<td>• Build platforms</td>
<td></td>
</tr>
<tr>
<td>• Anti-counterfeit initiatives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Primary Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Healthcare model innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Awareness of the impact of climate change on health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Investors</td>
<td>• Business ethics</td>
<td>• Business report</td>
</tr>
<tr>
<td>• Innovation</td>
<td>• Work plan</td>
<td></td>
</tr>
<tr>
<td>• Product quality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Healthcare model innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Employees</td>
<td>• Talent development</td>
<td>• Training</td>
</tr>
<tr>
<td>• Business ethics</td>
<td>• Career development planning</td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td>• Employee survey</td>
<td></td>
</tr>
<tr>
<td>Healthcare professionals / industry</td>
<td>• Anti-counterfeit initiatives</td>
<td>• Internal WeChat platform</td>
</tr>
<tr>
<td>• Innovation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Disease management development</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partners</td>
<td>• Sustainable supply chain</td>
<td>• Support training</td>
</tr>
<tr>
<td>• Business ethics</td>
<td>• Project partnership</td>
<td></td>
</tr>
<tr>
<td>• Healthcare model innovation</td>
<td>• Visit and communication</td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td>• Industry association events</td>
<td></td>
</tr>
<tr>
<td>Community public</td>
<td>• Innovation</td>
<td>• Health promotion</td>
</tr>
<tr>
<td>• Waste management</td>
<td>• Volunteer events</td>
<td></td>
</tr>
<tr>
<td>• Water management, including Pharmaceuticals in the Environment (PIE)</td>
<td>• Community projects</td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td>• Official website and WeChat public platform</td>
<td></td>
</tr>
<tr>
<td>Social organization / media</td>
<td>• Bioethics</td>
<td>• Project partnership</td>
</tr>
<tr>
<td>• Business ethics</td>
<td>• Press release</td>
<td></td>
</tr>
<tr>
<td>• Primary Care</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Anti-counterfeit initiatives</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Carbon emissions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Waste management</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Water management, including Pharmaceuticals in the Environment (PIE)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Awareness of the impact of climate change on health</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Stakeholder dialogues</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The material issues of Sanofi China

| Access to healthcare | • Innovation | • Disease management |
| • Primary Care | • Healthcare model innovation |
| Business ethics and R&D ethics | • Bioethics | • Business ethics |
| Local economic impact | • Sustainable supply chain | • Stakeholder dialogues |
| Patient safety | • Product quality | • Anti-counterfeit initiatives |
| • Pharmacovigilance | Talent development | • Talent development |
| Environmental footprint | • Carbon emission | • Waste management |
| • Water management, including Pharmaceuticals in the Environment (PIE) | • Awareness of the impact of climate change on health |
Contributing to corporate social responsibility through our four pillars and strategies

**CONTRIBUTING TO ACCESS TO HEALTHCARE**
- Foster access to healthcare for underserved patients

**UPHOLDING ETHICS AND TRANSPARENCY**
- Manage our activities with ethics and business integrity
- Protect patient safety
- Ensure medical ethics and bioethics

**ENGAGE WITH COMMUNITIES**
- Sustain ecosystems around Sanofi’s sites
- Develop and engage employees

**ADDRESSING ENVIRONMENTAL CHALLENGES**
- Reduce CO2 emissions
- Reduce waste
- Streamline water use and drug residues
- Increase awareness of climate change and its consequences on health

**HEALTHY PLANET**

**DEVELOPING OUR COMMUNITIES AND EMPLOYEES ENGAGEMENT**

Through the materiality analysis, Sanofi identifies the most material issues with closest relevance to Sanofi’s core businesses to develop the CSR strategy. Based on the results of analysis, Sanofi’s CSR approach focuses on the four key areas significant to corporate activities and stakeholders: Ethics and Transparency, Access to Healthcare for the Underserved, Engage with communities and Healthy Planet.

**CSR STRATEGY**

The external recognition received by Sanofi Group and Sanofi China demonstrates the outcomes of CSR management and commitment as well as the capability of sustainable development.

**OUR HONORS**

- In 2015 and 2016, Sanofi Group was ranked among the top 3 CSR performers in the pharma sector by the rating agencies (In 2015: Vigeo and MSCI; In 2016: Oekom and MSCI)
- In 2015, Sanofi Group was listed in the Carbon Disclosure Leadership Index (CDLI) again and obtained the CDP score: Climate change - B - 99 (full score: 100).
- In 2016, Sanofi Group obtained the CDP score: Climate change - A - Level “Leadership”; Water - B - Level “Management”
- Sanofi Group had been listed in Dow Jones Sustainability Index (DJSI) for 10 consecutive years
- Sanofi Group was listed in FTSE4GOOD (Financial Times Stock Exchange)
- Sanofi Group was listed in Access to Medicines Index (ATM)
- Sanofi Group was listed in Stoxx ® Global ESG Leaders indices
- Sanofi China won the “Social Responsibility Award – Excellent Company” at “China Social Responsibility Award Ceremony” for three consecutive years from 2015 to 2017
- Sanofi China won the “China’s Best Corporate Citizenship Award – The Company of the Year” consecutively in 2016 and 2017
- In December 2017, Sanofi China obtained the certificate of “2018 Top Employer in China” issued by Top Employers Institute
- In June 2017, Sanofi China won the title of Top 100 Most Attractive Employers from Health/Pharmaceutical Sector in Students’ Minds at “2017 Most Attractive Employer in China” Award Ceremony
- In December 2016, Sanofi Pasteur won the “Health China (2016) Annual CSR Model” Award
- In December 2015, the “2014 CSR Report” released by Sanofi China won the award of “Golden Bee 2015 Outstanding CSR Report- Enterprises from Foreign Countries, Hong Kong, Macao and Taiwan”
- In August 2015, Sanofi China won the international certification of “CEO Cancer Gold Standard” and became the first enterprise in China to receive this certification
- In March 2015, Sanofi China won the “Best Employer Award - Pleasant Working Atmosphere” at the “2015 China Randstad Award Ceremony”
- In January 2015, the “Teacher Assistance Public Welfare” project of Sanofi China won the “CSR Nomination Award” in the first “CSR China Education Award”
EMPOWERING THE ESSENCE OF ETHICS
ETHICS AND TRANSPARENCY

Ethics is the cornerstone of honesty and integrity. Sanofi is fully aware of the importance of keeping the ethical baseline and ensuring medication safety of patients to preserving the trust of stakeholders such as patients and communities and safeguarding our image and reputation. Sanofi considers ethics and transparency as the core of CSR strategy and is committed to continuously enhance product quality, business ethics and operational transparency to achieve the long-term support from stakeholders.
ENSURING PATIENT SAFETY

The quality and efficacy of pharmaceutical products have been the core needs of patients. Sanofi has been adhering to the concept of “patient first”, strictly complying with the regulatory requirements, continuously evaluating and monitoring the use and potential risks of products over the entire life cycle, and protecting safety of patients through strong global quality, PV, anti-counterfeit teams and a robust management system.

Enhancing quality management

Sanofi’s quality management covers all products and runs through every stage of entire product life cycle. Sanofi’s goal is to strictly comply with unified global standards from R&D, manufacturing, supply chain, distribution chain and PV to medical communication and patient support, meet the regulatory requirements in China, and ensure the safe and effective medication of Chinese patients.

In order to ensure the product quality in China, all the three plants of Sanofi China have set up high-standard production systems, and strictly implemented the Good Manufacturing Practice (GMP), e.g. the 24h non-stop air-conditioning system, the compressed air system higher than national standard and the advanced packaging system, during the production process. Sanofi Beijing Pharmaceutical Plant received the quality recognition from Australian Drug Administration and Japan Pharmaceutical and Medical Devices Evaluation Center, and successfully exported the products to these two countries.

In addition, Sanofi also places great emphasis on details of product design. For example, the Plavix tablets adopt the moisture-proof blister packaging, which can realize longer shelf life and unlimited storage conditions and avoid the quality problems caused by improper storage, and make use of the highly distinctive pink coating with signs from Monday to Sunday to prevent misuse or omission.

Major measures of Sanofi China to enhance quality management

1. Standards and norms
2. Key issues control (Storage and transportation control, etc.)
3. Monitoring and auditing
4. Improved awareness and capabilities (Quality fundamentals e-learning program, etc.)
5. Quality fundamentals training launched by the three plants of Sanofi China

Adopting new vaccine distribution model to facilitate safe delivery of high-quality vaccines

In 2016, the State Council of China amended the “Regulation on Circulation and Vaccination of Vaccines” to issue new requirements on vaccine distribution process. Sanofi Pasteur, the vaccines BU of Sanofi, immediately commenced to plan the new vaccine prediction and distribution model, including the creation of a new distribution center to cover more than 2,000 CDCs in China; and the comprehensive enhancement of cold chain storage and transportation quality management to ensure that the customers can receive the vaccines with assured quality as early as possible.

After leaving the production bases, Sanofi’s vaccines can be delivered directly to CDCs across China within 48 hours. In addition, the distribution centers of Sanofi China in Guangzhou, Hangzhou, Beijing and Chengdu are operated by professional third-party logistics providers and are fully regulated by Sanofi China to ensure the safe, timely and economical distribution of vaccines.

Facts and figures:

- By the end of 2016, nearly 94,000 employees of Sanofi Group accepted the quality fundamentals training
- The supply chain of Sanofi covers more than 1,700 cities and towns in China
- Sanofi China successfully compiled the Sanofi “Quality +” - Sanofi China Quality Report
Enhancing PV monitoring

Sanofi monitors global product safety through the Global Pharmacovigilance (GPV). The GPV has set up global organizations such as PV teams in 86 countries and regions including China. GPV continuously and effectively collects PV data from different sources in 24 hours depending on the hot-lines and digital platforms of Sanofi PV Management System. At the same time, GPV comprehensively and timely monitors and evaluates the adverse drug reactions to achieve global linkage and information sharing for safety of products and health of patients.

Sanofi also provides product safety information through the official website, and has established strong interactions with stakeholders across the world in clinical development and product lifecycle management to ensure the integrity of safety data collection process as well as the effectiveness of safety assessment (complying with all applicable laws and guidelines including the strict data privacy principles). In November 2015, Sanofi also launched the internal “PV Promotion Week” to promote PV knowledge and improve awareness of employees through internal communication.

Anti-counterfeit initiatives

In order to ensure medication safety of patients, Sanofi has set up dedicated product safety teams across the world to cope with the severe challenges from counterfeit initiatives facing the entire pharmaceutical industry. The product safety team of Sanofi China actively cooperates with relevant internal departments and the external agencies such as public security, CFDA, customs and drug safety associations in China to jointly publicize the principle of “protecting medication safety of patients, and fighting against various forms of anti-counterfeit initiatives” and assist the public security agencies every year to crack down on the criminals who manufacture and sell counterfeit initiatives. Meanwhile, Sanofi China has developed the “Anti-counterfeit initiatives” module on the WeChat enterprise platform as a channel for reporting suspected counterfeit information by internal employees.

In order to combat counterfeit initiatives, Sanofi has improved the methods of sampling, analysis and data collection, set up the global anti-counterfeit lab, and worked with global regulatory agencies, and adopted advanced facilities and technology to analyze the suspected samples on the market, prevent potential medication risks and safeguard medication safety of patients. In addition, Sanofi has also selected June 8 as the “Sanofi Global Anti-Counterfeiting Day” to enhance the public awareness and insight on counterfeit initiatives across the world.

Facts and figures:

- Since the opening in 2008, Sanofi Global Anti-Counterfeiting Lab has recorded more than 30,000 samples for analyzing potential counterfeit initiatives.

RESPONSIBLE MEDICAL INFORMATION PROMOTION

The pharmaceutical product information directly affects the clinical medication of physicians and treatment of patients. Sanofi China adheres to the medical promotion in a moral, objective and scientific manner and injects ethics and compliance into the mind of every employee to provide scientific and reliable academic information and product information for patients, healthcare professionals and regulatory agencies and ensure that the products can maintain high efficacy and safety and better benefit the patients.

Sanofi China requires that all promotional materials shall not exceed the scope of indications in the package inserts, and materials used must be approved by the Medical Department and the Registration Department to provide adequate evidence for product promotion; the non-promotional materials shall not aim at promoting the prescriptions, and shall provide academic progress on products or diseases at a neutral position.

In addition, through the 4M (Medico-Marketing Materials Management System) online approval system, Sanofi China has uniformly approved over 17,292 marketing and medical materials online since 2015 (4,989 materials during the first half of 2017 only), which include promotional materials, medical slide tool kits, training and communication information, etc. In order to better regulate approval of materials and reduce approval risks, Sanofi has recently optimized the system on the aspects such as increasing the approval of medical managers in the certification stage.

All the medical information communication representatives of Sanofi China are certified by the R&D-based Pharmaceutical Association Committee (RDPAC) to ensure that they have high standard professional and ethical qualifications.

Facts and figures:

- For the PV training sessions in medicine for medical information communication representatives, Sanofi China has provided 68 training sessions and 1,04,100 person-times in the first half of 2017.

- For the PV training sessions in medicine for medical information communication representatives accepting training, Sanofi China has provided 68 training sessions and 1,04,100 person-times in the first half of 2017.
BUSINESS ETHICS

Sanofi advocates doing the right thing and complying with applicable laws and Sanofi policies to ensure the business ethics while achieving business targets, implement corporate level business ethics promotion plan and address the challenges of business ethics.

Sanofi attaches great importance to maintaining business ethics in daily business activities, and has developed a Code of Ethics available in 29 languages for all employees. In 2016, Sanofi upgraded the compliance department to the Ethics & Business Integrity (E&BI) to lay a solid foundation for comprehensively implementing the guidelines of ethics.

Sanofi has set up the executive EBI committee to help and ensure the effective operation of all aspects of Sanofi Compliance and Business Ethics program, identify and review any trends, issues and ethics & compliance events with potential impact on Sanofi, and ultimately commit to creating a culture deeply in mind within the organization, namely doing the right thing and complying with relevant laws and Sanofi policies. Sanofi has the China EBI committee responsible for overseeing, supporting and guiding compliance efforts of Sanofi China.

In addition, based on the Code of Ethics addressing 15 topics relating to ethical matters, Sanofi China actively conducts employee-level compliance training, and collects complaint information through the dedicated 24/7 confidential Compliance Helpline.

Based on the compliance ambassador program launched by Sanofi China in 2016, Sanofi has also set up the network of compliance ambassadors with an aim to communicate and enhance global compliance information, improve risk assessment and awareness of potential issues, encourage opinions of employees, and support the development of business ethics and integrity.

Global promotion of local practice - Sanofi China Compliance Ambassador Dandelion Program

In 2016, Sanofi China launched the Compliance Ambassador Dandelion Program, and achieved excellent outcomes. In order to deeply insert the compliance culture into the core businesses and better communicate the concept of compliance to all departments and employees, the Sanofi Compliance Ambassador Program started the global promotion at the initiative of the Sanofi Global Compliance Ambassador. In China, the program mainly conducts daily communication with the compliance ambassadors through the WeChat enterprise platform and the WeChat mini courses, and promotes the program through different models such as mentor system and monthly meeting of compliance ambassadors.

Major responsibilities
- Information transfer and project support
- Training
- Assistance in monitoring
- Communication
- Promoting compliance culture

New expectations
- Participation and assistance of supporting functions
- Effective interactions with ambassadors/mentors, e.g. sharing of actual cases
- Introduction of new technical platforms, e.g. WeChat enterprise account
- Expansion of projects
- Participation and assistance of supporting functions
- Effective interactions with ambassadors/mentors, e.g. sharing of actual cases
- Introduction of new technical platforms, e.g. WeChat enterprise account
- Expansion of projects

In addition, the Compliance Ambassador Program has also set five key performance indicators of “Role Models, Compliance Training, Policy Experts, Chief Trainers and Communication Bridges”, which set out the requirements of various indicators in details to better evaluate the compliance ambassadors.

Facts and figures:
- In 2016, Sanofi China conducted the compliance training for 51,012 person-time
- Sanofi China Compliance Ambassador Dandelion Program includes 115 compliance ambassadors, the number of compliance ambassadors from business units were increased from 42 to 160, and 15 compliance ambassadors from supporting functions were newly added.
MEDICAL ETHICS AND BIOETHICS

Throughout the activities such as clinical study and animal experiment, Sanofi has been actively addressing the ethical challenges and promoting responsible clinical practice and scientific advancement by respecting and continuously revising and improving constant bioethical standards.

Sanofi Bioethics Committee develops Sanofi’s bioethics policies and supports the Sanofi Risk Committee to ensure ethical conduct in clinical development involving patients and healthy subjects (including respect for human dignity and the protection of animals).

In response to the ethical challenges of animal experiment, Sanofi China has partnered with Chinese Association for Laboratory Animal Sciences and Beijing Laboratory Animal Society to launch animal protection and utilization initiatives since July 2013 to ensure that the partners meet Sanofi’s principles on animal welfare, improve the awareness on animal welfare in China and advocate ethical animal study. Sanofi fulfills its obligation to conduct moral and legal animal study, and Sanofi China’s R&D department advocates ethical animal study with local partners to bring them in line with the international and national standards on animal experiment. In addition, Sanofi promotes the veterinary training on animal experiment in China, so that they can advocate animal welfare and provide humane care for the animals in experiment.

Measures of Sanofi for addressing the ethical challenges in clinical study in 2016

Informed Consent Form
Improved template to be used in clinical trials

Patients and volunteers
Adaptation of our framework for evaluating the ethics of our clinical research studies

Human biological samples
A unified company solution with high ethical standards is in process to conform sample management across all Sanofi organizations

Research activities
Continuous adaptation of our activities to the international Nagoya treaty on biodiversity. Full implementation of the new processes is expected to be organized throughout 2017

Animal use in research and drug and vaccine production
Continuous implementation of the 3Rs (Replacement, Reduction and Refinement) principles

Facts and figures:

- Between 2015 and 2016, Sanofi reduced 10% in animal use through improvement or development of new techniques
- In 2015, Sanofi China trained 60 animal experiment veterinarians through animal protection and use initiative activities

RESPONSIBLE PROCUREMENT

Sanofi regards responsible procurement strategy as an integral part of our supply chain, and works closely with our suppliers so that they will take CSR principles on board and comply with the high standards of Sanofi.

Supplier Risk Management

Since 2007, Sanofi has developed a risk management model for the large-scale and targeted evaluation of our suppliers worldwide, and provided risk mapping per procurement category and risk-exposure mapping per country, etc. to address a full range of procurement risks.

Assess and support development of suppliers

In 2016, Sanofi joined the Together for Sustainability (TfS) initiative, thereby becoming the first French-based healthcare company to become part of this initiative based on established principles, such as the UN Global Compact and the Responsible Care Global Charter. This initiative gives Sanofi access to a large shared platform of supplier assessments and audits and the opportunity to share best practices with our peers.

In addition, Sanofi became a member of the Pharmaceutical Supply Chain Initiative (PSCI) involving 24 pharmaceutical and healthcare companies at the beginning of 2017. The PCSI encourages continuous improvement and compliance of their suppliers in regard to better social, environmental and economic performance.

In order to better assess and support development of suppliers, Sanofi has also joined the two major work programs of supplier shared audit and supplier performance improvement.

Facts and figures:

- Since 2014, 473 suppliers of Sanofi have accepted CSR compliance assessment
- In 2016, Sanofi conducted 86 supplier shared audits
- In 2016, the proportion of local procurement amount of Sanofi China reached 98%
EMPOWERING THE SOURCE OF LIFE
ACCESS TO HEALTHCARE FOR THE UNDERSERVED

Sanofi China upholds the principle of “patient first” to make full use of Sanofi’s in-depth understanding to the healthcare industry and disease management, enhance the access to healthcare for the underserved through diversified and sustainable development, provide the Chinese people with scientific and professional medical and healthcare services, and promote the level of public health.
CONTINUOUS INNOVATION FOR PATIENTS

Innovation is the cornerstone of Sanofi’s sustainable development. As a globally leading healthcare enterprise, Sanofi China is committed to providing innovative treatment options for Chinese patients and enlarging the investment to meet the increasing demand of Chinese patients and ensure timely and continuous supply of high quality innovative drugs and vaccines to patients and consumers.

Relying on the strong innovation capability of Sanofi Group, Sanofi China has introduced more than 40 kinds of drugs and vaccines covering various disease areas into China to meet the health needs of Chinese patients. Sanofi China also gives full play to the strength of China R&D center and Asia Pacific R&D Hub and explores the potential of local innovation. For example, Sanofi China and Shanghai Institutes for Biological Sciences (SIBS) have established a strategic partnership since October 2008, and jointly launch the “Sanofi-SIBS Young Talent Scholarship” program to encourage young researchers to explore their potentials and contribute to scientific innovation.

Facts and figures:
- Launched more than 60 strategic cooperation programs with top scientific research institutes in China
- There have been more than 300 R&D employees in China
- Introduced more than 40 innovative drugs and vaccines

Implement industrial partnership

In order to continuously boost the progress of healthcare industry in China, Sanofi China actively partners with industry players to give full play to respective advantages and work together to promote the innovation and development of healthcare industry in China.

Develop affordable high quality biologics

In December 2016, Sanofi and JHL BIOTECH established a strategic partnership to achieve complementary resources and mutual benefits. Sanofi integrated the capabilities of JHL BIOTECH on R&D and production, and combined own advantages in commercialization of pharmaceutical products to improve the accessibility of biologics and bring affordable pharmaceutical products with higher quality to Chinese patients. In February 2017, the two parties submitted the clinical trial application to the China Food and Drug Administration (CFDA) for JHL1101 (rituximab biosimilar), the first drug developed through the partnership for non-Hodgkin lymphoma, and expected to bring the product meeting the global high quality standards in China as soon as possible to meet the needs of more Chinese patients.

Innovative drugs for rare diseases

As a pioneer and leader in the field of global rare diseases, Sanofi Genzyme has introduced the drugs for rare diseases such as Gaucher disease and Pompei disease since the entry into China market to improve the accessibility of these innovative drugs. In China, we have helped more than 100 patients with Gaucher disease through our charity program.

Facts and figures:
- Covered 23 provinces and cities
- Benefited more than 130 patients
- Helped more than 50 adult patients return to work
- Helped more than 50 teenage patients to return to school

Improve the accessibility of drugs for Pompe disease in China

Pompe disease is a kind of rare disease with the neonatal morbidity of about 1/40,000, and there are only 100+ patients diagnosed with Pompe disease in China. Many clinicians also lack knowledge about it, so the patients are often misdiagnosed and missed.

At the end of 2016, Myozyme, a kind of innovative drug of Sanofi and also the only drug targeting the root cause of Pompe disease in the world, was approved by CFDA for the treatment of patients with Pompe disease in China’s Mainland.

Through the enzyme replacement therapy, Sanofi changes the course of Pompe disease and achieves the clinical outcomes to help patients improve or maintain muscle function, stabilize the respiratory system, maintain a high survival rate, and make Pompe disease a rare disease with effective treatment method. In the future, Sanofi will continue to make more efforts to improve the diagnosis and treatment of rare diseases and to join hands with various parties in exploring the sustainable development of treatment for rare diseases.

Digital health platform

With the development of digital information technology and the increasingly optimized mobile devices, the demands of patients and healthcare professionals for mobile healthcare have been rising sharply. Sanofi China continuously pioneers the innovative and diversified business models to promote the transformation of healthcare model.

Build up the “MC2” platform to improve the efficiency of medical information access

In July 2017, Sanofi China launched a new free medical information communication and management platform - “MC2”, which provides accurate, personalized and professional academic information and services for healthcare professionals (mainly county level physicians at present) through innovative and diversified communication channels and dissemination models.

In order to improve the efficiency of physicians to obtain useful information and better meet their professional needs, the “MC2” program has formed a new professional online medical consultant team, which takes the initiative to know the academic needs of physicians, deliver professional academic information and provide customized content feedback through various channels. Through the long-term point-to-point communication and interaction with physicians, the program seeks to promote their understanding to the clinical application of drugs and help them improve their medical and academic capabilities.
In 2015, "CONCEPT", the chronic disease management platform jointly developed by Sanofi China and leading domestic mobile Internet companies, was officially launched. As the first chronic disease management mobile platform focusing on the county level market, it gives priority to the fields of cardiovascular diseases and diabetes with the largest patient groups in China. The "CONCEPT" platform promotes the communication and follow-up between physicians and patients, enhances continuing education of physicians, better manages patients with chronic diseases through big data analysis, and helps to build online hierarchical diagnosis and treatment systems among hospitals, which can fully reflect the innovation of medical services under the trend of "Internet +" and provide a new way to solve the pain points of county level medical system.

In 2017, "CONCEPT" received the “First Excellent Chronic Disease Management Platform in China” award, and became the only award winning management platform developed through the strategic partnership between a healthcare enterprise and the Internet companies.

**"CONCEPT" digital platform to improve county level diagnosis and treatment for chronic diseases**

**Facts and figures:**
- Since its launch in October 2015, the "CONCEPT" program has covered more than 1,500 county level hospitals.
- It has benefited more than 30,000 medical practitioners.
- It has benefited more than 50,000 patients.

**IMPROVE ACCESS TO HEALTHCARE**

Due to the inseparable relationship between the accessibility of medical services and public health, Sanofi China meets the urgent needs for disease prevention and control and truly benefits the public in need through continuously developing its businesses and industrial partnership to meet the growing public demand for drugs and medical services.

**Promote the development of primary care**

In recent years, the primary care infrastructure has been significantly improved, and the number of patients accepting diagnosis has also been on the rise. However, compared with the huge patient population, the needs of primary care system on hospital management, professional capabilities of medical practitioners and management of patients and diseases are not met, and the conflicts are increasingly highlighted. Sanofi China actively follows the trend of health reform in China, and continuously promotes the distribution in county and community level medical services to promote the development of primary care.

- **Contribute to the development of county level medical services in China**
  
  The gap of economic and social development between urban and rural areas in China is obvious, the distribution of medical resources in urban and rural areas is not balanced, and the development of county level medical service clearly lags behind. In 2011, Sanofi China initially entered the county market with an independent business unit. Through the deep exploration for years, it has brought advanced solutions and standardized diagnosis and treatment concepts to the county level physicians in China to support the improvement of county level medical services and achieve the goal of "addressing minor diseases within towns and serious diseases within counties".

**County level hospital chest pain center program to protect the lives of patients with myocardial infarction**

For the patients with myocardial infarction, time is crucial. At present, the number of chest pain centers in county level hospitals can hardly meet the needs of primary level patients, who often waste the precious treatment occasions on the way to large hospitals in urban areas.

In 2016, Sanofi China and China Cardiovascular Association signed the framework agreement on county level chest pain center (CPC) and launched the "County Level Hospital CPC Construction and Interventional Diagnosis & Treatment Enhancement Program", which supports the systematic training for cardiovascular physicians in county level hospitals, enhances the construction of county level CPCs and improves the clinical capabilities of interventional treatment for cardiovascular diseases in county level hospitals. Through this program, Sanofi China seeks to improve the level of prevention and treatment for cardiovascular diseases in China, promote the standardized development of diagnosis and treatment for cardiovascular diseases, facilitate the implementation of hierarchical medical system and benefit more county level patients with myocardial infarction.

**Facts and figures:**
- “The construction of county level CPCs will systematically improve the basic conditions of treatment for acute chest pain and form the pre-hospital first aid and in-hospital green channels, including the completion of connection with external first aid systems, the joint rescue agreement and collaboration network with lower-level medical institutions as well as the county level coordinated medical system.”

Professor Huo Yong, the Director of Heart Center, First Hospital of Peking University
Help to improve the community healthcare in China

In the entire disease prevention and control system in China, the community health service centers play a critical role as an important component of primary care. Only the overall improvement of community healthcare can truly achieve the model of "first diagnosis in communities, serious diseases in hospitals and rehabilitation in communities". Sanofi China is committed to providing integrated solutions and knowledge sharing for the community medical practitioners and making full use of various advantages and resources to establish the most vital ecosystem in community healthcare and ultimately benefit the patients.

Launch the “Healthy Community” program to improve the level of community healthcare

Sanofi China upholds the commitment to "In China, for China", and joins hands with various organizations such as Chinese Medical Doctor Association and Community Health Association of China to launch the strategic "Healthy Community" program and meet the urgent needs on community health services and disease management through building a three-dimensional comprehensive enhancement program and exploring effective community chronic disease management.

In the process of implementation, Sanofi brings the knowledge and experience on chronic diseases such as cardiovascular and cerebrovascular diseases, diabetes and central nervous system diseases to the communities to improve the clinical skills of community medical practitioners and enhance the capabilities of hospital managers. Then, the disease management capabilities of patients with chronic diseases will also be improved, and more Chinese patients will benefit from the excellent community health services.

Facts and figures:

• As of July 2017, the “Healthy Community” program of Sanofi China covered 3,176 hospitals and supported the training for 5,986 community physicians

Enhance disease and health management

Sanofi China actively utilizes its own advantages to provide Chinese people with accurate diagnostic services and disease prevention advice, which will help to achieve the goal of “Healthy China 2030”.

Provide assistance for prevention and treatment of chronic diseases such as diabetes

China is a big country of chronic diseases with a rising prevalence rate. As a leader in the field of chronic diseases, Sanofi China leverages the extensive experience in chronic disease management and diversified high quality portfolio of innovative products, and collaborates with the medical professionals to launch strategic medical programs, collectively address the challenges of chronic diseases and benefit the public.

Make active investment to eliminate the management gap of patients with diabetes

According to the statistics of International Diabetes Federation (IDF) in 2015, there were 114 million patients with diabetes in China, and 90% of them had type 2 diabetes. However, as many as 70% of them failed to control their blood sugar adequately. It was a huge task to help them take drugs correctly and achieve the qualified treatment and life quality.

In 2014, Sanofi China and Chinese Medical Doctor Association jointly launched the “TRIO” program focusing on the huge gap in self-management of patients to organically integrate the medical practitioners and the patients, launch the systematic management for the patients accepting outpatient insulin therapy and promote the standard use of basic insulin through the computerized systems and modern communication methods such as PAD and SMS platform. The “TRIO” program can help the patients monitor their blood sugar, adjust insulin dosage, and further improve the compliance with treatment plans to conveniently and effectively implement the blood sugar monitoring and treatment plans and achieve qualified fasting blood glucose. In 2015, the program covered more than 140,000 patients with diabetes, and 73% of them achieved qualified fasting blood glucose. In 2016, the program benefited more than 147,000 Chinese patients with diabetes.

“The number of patients with chronic diseases in China is rising rapidly, and there are 260 million patients diagnosed with chronic diseases. It has been a major public health issue, which will bring about serious social and economic problems if we fail to control it in an effective and timely manner.”

Source: China Chronic Disease Prevention and Control Plan (2012-2015)
Focus on the health needs of patients with insomnia

As people’s lifestyle changes, insomnia has gradually become one of the most common public health problems in China. Sanofi China launched the Nobbie program to establish Nobbie Sleep Centers, which can provide the patients with more comprehensive and in-depth treatment plans and services and also publicize relevant medical information to the public to help them understand insomnia correctly.

Promote disease prevention

Disease prevention and control has been a major demand of medical and healthcare services in China. Adhering to the goal of rooting in China, Sanofi Pasteur not only devotes itself to providing high quality and safe vaccines for Chinese people, but also responds to the call of “Healthy China 2030” to build up an academic platform and promote the improvement and development of immunization and vaccine technology.

At the same time, in order to make the public obtain scientific knowledge on vaccines, improve public awareness of disease prevention and eliminate the prejudice against vaccines, Sanofi Pasteur, in collaboration with the CDC of Chaoyang District and CCTV, produced a public documentary on vaccines and infectious diseases to communicate the knowledge on vaccines and disease prevention comprehensively, scientifically and authentically.

History of new vaccines introduced in China by Sanofi Pasteur

- 1995 Introduced rabies vaccines
- 1996 Introduced inactivated polio vaccines
- 1997 Introduced Haemophilus conjugate vaccines for influenza type B
- 2009 Introduced IPV
- 2011 Introduced pediatric 5-in-1 combination vaccines

Promote the inclusion of inactivated polio vaccines (IPVs) into the National Immunization Plan

As the world’s largest provider of Inactivated Polio Vaccines (IPV), Sanofi Pasteur has been actively coordinating the Global Polio Eradication Initiative of the World Health Organization (WHO). As a strategic partner of disease prevention and control, Sanofi Pasteur has been actively promoting the pilot programs in response to the transition of national polio prevention and control strategy and providing the high quality IPV’s. Sanofi Pasteur will continuously provide Chinese people with more targeted vaccines and contribute to the disease prevention and control in China.
EMPOWERING THE BEAUTY OF HUMAN NATURE

ENGAGE WITH COMMUNITIES – DEVELOP AND ENGAGE EMPLOYEES

The development of talent is the key to continue to enhance competitiveness and to support the successful implementation of the 2020 strategic roadmap of the group in an increasingly complex environment. Sanofi China pursues the global talent development concept of “One Sanofi, One HR”, devotes itself to providing every employee with perfect training and development opportunities, in order to help them develop their dreams and potential and realize their pursuit of life value.
EMPLOYEES DEVELOPMENT

Advocating diversity and inclusiveness

As a large multinational healthcare company, Sanofi China strictly adheres to the local labor standards in various regions of the country and effectively fulfills all the legitimate rights and interests of the staff. We recognize and respect the diversity of employees, and strive to create diverse and inclusive working culture atmosphere for employees, so that employees of different nationalities, ages and genders have fair opportunities for development.

- **Sex ratio of Sanofi China employees 2016**
  - Male employees: 51%
  - Female employees: 49%

- **Age composition of Sanofi China employees 2016**
  - Aged 30 and under: 44.65%
  - Aged 31-40: 45.77%
  - Aged 41 and above: 9%

To promote gender balance and drive cultural diversity, Sanofi China has established the Chinese Women’s Leadership Committee, and has established the three tasks of “work-life flexibility”, “women’s leadership” and “from women to women”. The key project, CATALYST Program, helps women solve obstacles in their careers, establishes women’s self-consciousness and confidence, and enhances their influence and execution in the workplace.

**Facts and figures:**

- In 2015-2016, the number of job rotation employees that Sanofi group sent to the Sanofi China is **81**
- From 2015 to 2016, **142** women have participated in the “CATALYST Program” for female managers, and the average score of their satisfaction survey was 4.9 points (full mark is 5 points). **100%** of the participants thought they would recommend the program to their colleagues.
- Sanofi regularly conducts global employee surveys, which are performed by third party companies, and organizes forums and sharing meeting to communicate with employees, and develops plans for improvement.
- As of 2017, more than **70%** of the employees in Sanofi China plants signed a collective agreement, which will be valid until 2019.

**Setting up the stage for the development of business**

Helping employees to realize their career development and life value is the important mission that Sanofi China commits to the growth of its employees. We provide diverse training and unimpeded career development opportunities for employees, helping employees create meaningful career and empower their life ideals and values.

**Sanofi University**

Sanofi University, founded in 2007, is one of the famous internal training institutions in the healthcare industry. It has a strong internal training team and a rich training course. In recent years, through the establishment of the four functional teams “national BU training team, new hire training team, assessment & quality control team, and market access team”, Sanofi University provides systematic, comprehensive training courses and learning opportunities for employees at Sanofi China, especially the medical information communication representative team, helping the staff to improve their skills and display their talents.

Specifically, Sanofi University integrates training resources from each BU and business region in Sanofi China, provides training courses about compliance, basic skills and professional skills, leadership and personal growth for employees, and adopts the training mode combining multidimensional online training (E-learning) and offline training (Classroom teaching), which enables employees to choose appropriate learning methods according to their individual needs, and strives to meet all-round and multi-level training needs of staff.

**Facts and figures:**

- The total training hours for employees at Sanofi China is **404,228** hours for classroom teaching course and **186,532** hours for E-learning course.
- The number of courses offered by Sanofi China is **515**
Comprehensive plan for talent development

Sanofi group has established the four pillars of human capital strategy, seeking to motivate and develop excellent talents through strong talent training and support system, and supporting the implementation of Sanofi 2020 strategic roadmap.

Sanofi China, adhering to the group’s human development concept, encourages employees to pursue a diversified career. We use the leadership ability model to assess the status of employees’ career development and make a comprehensive career development plan for them. We provide trans-department function exchange, overseas job rotation communication, internal promotion, and support employees to accomplish their career development by actively using the group’s advantages of globalization, thus helping Sanofi China to create a talent team with sustainable development.

Cultivating the future leadership of employees

The core values of “teamwork, courage, respect and integrity”, as well as the leadership competency of “act for change, cooperate transversally and develop people” are the two cornerstones to ensure the success of talent strategy. To train leaders in line with Sanofi culture, we start the “global leadership development project” to help senior staff managers improve their management and leadership. At the same time, we will further study the key capabilities of all stages of staff development, develop related learning and training courses, and systematically promote the development and upgrading of talents.

Facts and figures:

- 2015-2016, the number of employees that Sanofi China sent abroad for job rotation: 5
- MBA program offered by Sanofi China together with China European International Business School: since 2008, it has been held every two years. As of 2016, it has been held four times. A total of 136 employees graduated from the program, in which 27% of the staff got promotion, 14% of the staff achieved internal job rotation.

A HEALTHY AND COMFORTABLE WORKING ENVIRONMENT

Sanofi China is continuously improved the health, safety and environment (HSE) management system, providing employees with comprehensive safety protection measures, abundant health insurance activities and various welfare systems, so as to create a healthy and comfortable working environment for employees.

A safe place for work

The HSE department at Sanofi China carries out a safe inspection of the workplace every day, equips air cleaners for all offices as well, and regularly detects indoor air particulate matter concentration, to prevent all kinds of potential health and safety risks, and ensure employees can work in peace and happiness.

Facts and figures:

- In 2016, the incidence of safety accidents of man-hours loss * in Sanofi China was 0.25%, and the number of safety production accidents was 4.
- **Incidence of safety accidents of man-hours loss = man-hours loss during the base period / 1,000,000 / working hours in the base period; the number of safe production accidents = safety accidents with man-hours loss + safety accidents without man-hours loss.
- In 2016, Sanofi China carried out 7 office first aid training, covering 12 cities, a total of 159 employees passed the primary first aid.

Sanofi China is equipped with AED equipment in the office and carries out the First Aid Training.

Facts and figures:

- In 2016, the number of maternity leave / paternity leave: 227 / 229
- Return number of maternity leave / paternity leave: 431 / 435
- The number of maternity leave / paternity leave and their return number of Sanofi staff from 2015 to 2016 (The return number in 2016 is up to July 31, 2017)
The “Bwel!” program cares about the physical and mental health of the staff

Sanofi China is the first company who got the “CEO Cancer Gold Standard” international certification in China, and the promotion of “Bwel!” workplace health program has played an important role. Since the introduction of the “Bwel!” program in 2013, we have established three major health pillars of “Eat Well, Move Often and Feel Good”. The program has been carried out continuously and has been gradually promoted to the regional offices nationwide, in order to enhance the health of the staff and prevent or delay the occurrence of non-infectious diseases.

We also regularly evaluate the lifestyle of employees, so as to help them identify potential health risks and provide them with a personal health management scheme.

Employee welfare and care

Sanofi China advocates work-life balance, in addition to supporting employees’ career development, it also provides various health benefits for employees and their families, and promotes employee engagement and sense of belonging.

At the same time, we establish and continue to improve the competitiveness of the overall salary and welfare system.

Stock purchase plan of employees

In 2016, Sanofi China launched a new communication platform for overall salary and welfare, in addition to the national legal remuneration and welfare, to further improve the various supplement welfare with Sanofi characteristics, such as comprehensive and flexible benefit plan, annual physical examination for the staff and children, free vaccination for the staff and their families and stock purchase of employees, in order to attract, motivate and retain talent.

In 2016, Sanofi China launched a Worldwide Employee Stock Purchase Plan, in which employees can buy company stock at a certain price below the market price in a certain ratio, and become a shareholder and enjoy dividends.

Summer vacation exchange plan

With the resources of Sanofi all over the world, employees’ children from different countries and regions can establish contacts through the summer vacation exchange plan, and spend special holidays in the countries where each other’s families are located.

Sanofi family care fund

The family care fund gives a certain relief to employees of Sanofi China in the event of a sudden financial difficulties or an accident facing the individual or his/her immediate family.

Enfants de Sanofi

It is a special relief for children of difficult employees, including funding for health care, life and education. This Sanofi foundation also carries out a series of activities such as summer painting competitions, environmental education, and so on.

Facts and figures:

- As of 2017, the “Bwel!” program covers 11 regional offices in China, which engaged more than 7,000 employees.
- In 2016, the “Bwel!” program has carried out 7 kinds of activities; the employee participation time was 1,350 hours; and the person times of employee participation was 22,000.
- In 2016, the number of employees who involved in health risk assessment was 806.
- 2015-2016, a total of 32 employees’ children at Sanofi China participated in the summer holiday exchange program.
Sanofi China pays close attention to the community construction where they operate, aiming at improving the inclusiveness and sustainability of the community ecosystem, providing help for the people who need care, and empowering their lives.
VOLUNTEER SERVICE

Since launching volunteer activities, Sanofi China has continuously developing and expanding “Sanofi Hope Volunteer Group” throughout the country, and has continued to carry out various public welfare programs jointly with all sectors of society. “Sanofi Hope Volunteer Group” play their expertise in health, focusing on helping the sick children and the teenagers with limitation of self-development, and promoting their healthy growth.

“Sanofi Hope Volunteer Group” has launched a number of public welfare programs in Shanghai, Nanjing, Changsha, Beijing, Guangzhou and Chengdu, such as “Kid Strong” program caring for children of migrant workers in Shanghai, “Gold-ribbon” program for helping cancer patients and their parents in Guangzhou, “Firefly” program for supporting children with special difficulties in Liangshan which is led by Chengdu team, etc.

For improving the professionalism and sustainability of the volunteer group, we rely on the professional CSR advisory committee, to provide professional training for the leader and backbone of each volunteer group. At the same time, Sanofi China provides one day of “volunteer paid time off” for each employee to encourage and support the employees to actively participate in the volunteer group activities.

Empowering children with love

On October 27, 2017, the first “Sanofi Hope Volunteer Day” kicked off nationwide at the same time in 12 cities including Beijing, Shanghai, and Guangzhou. Hundreds of Sanofi employee volunteers walked into the local community, hospital and rehabilitation institutions, together with the NGO partners, sent love to more than a thousand sick children. Taking “Empowering Children” as the theme, this volunteer day focused on serving the sick children, through different types of interactive activities such as ward visits, organizing baking, art education, fun sports meeting and so on. They brought more laughter and hope for children with epilepsy, leukemia, brain injury, cancer and autism. As employees of healthcare enterprises, many Sanofi volunteers have knowledge background in health, and they actively contribute their expertise when participating in volunteer activities.

Facts and figures:

As of 2017,
• “Sanofi Hope Volunteer Group” has more than 600 regular members
• It has carried out more than 300 voluntary activities
• 7,000 people-times of employee volunteers participated in it
• It had more than 40,000 beneficiaries

Fighting against poliomyelitis • Great love with no words – Sanofi Pasteur concerns Pizhou New Hope Center

As the world’s largest provider of inactivated polio vaccine, Sanofi Pasteur actively promotes the development of public health and prevention in China. Since 2012, Sanofi Pasteur has carried out many public benefit activities in Pizhou New Hope Center, donated rehabilitation treatment apparatus and rehabilitation training equipment, and appealed to the society and the public for the prevention of poliomyelitis. In May 2017, Sanofi Pasteur launched a public welfare campaign focusing on “fight against polio, great love with no words – Sanofi concerns Pizhou New Hope Center”, contributing RMB 200,000 to help disabled children in Pizhou New Hope Center get better rehabilitation treatment. The volunteers of the “Sanofi Hope Volunteer Group” were also actively involved to take care of the disabled children.

Volunteers of “Sanofi Hope Volunteer Group” continue to be active at the Pizhou New Hope Center

Volunteering to help children with autism try art therapy, and perceive the world with painting. Shanghai: Sanofi volunteers gave an interesting Halloween party for children with blood tumor in Shanghai Children’s Medical Center.
HUMANITARIAN AID

Taking root in China for 35 years, Sanofi has been actively involved in humanitarian disaster relief activities. From providing rehabilitation support for the wounded after the earthquake to funds and drug assistance after emergency, we pay close attention to the needs of the disaster affected groups, and give full play to the professional advantages to help the local communities.

“Intervention of Care” program assists the comprehensive rehabilitation of the wounded in earthquake

Originated in 2008 following the Wenchuan earthquake, “Intervention of Care” is a comprehensive rehabilitation program for the wounded after the earthquake, funded by Sanofi China and launched by Handicap International and You & Me Community, in order to improve the physical and psychological rehabilitation of the wounded after the earthquake as soon as possible and to an extreme, to promote the rapid return to the family and society.

Over the years, “Intervention of Care” program has been involved in the post-earthquake relief in Wenchuan, Mianzhu, Yushu, Ya’an, Lushan, Ludian and other places, accumulating a complete comprehensive rehabilitation service practice and experience for the wounded of post earthquake, and making a positive contribution to rehabilitation services for earthquake victims in China. At the same time, “Intervention of Care” program also focuses on improving the comprehensive level of rehabilitation in local hospitals, so as to ensure that the hospital can provide high-quality rehabilitation services for the wounded and other patients in the long run.

Provide hospital rehabilitation in the emergency stage
- Provide rehabilitation service and rehabilitation equipment
- Promote the awareness of standardized operation process of hospital management and medical staff
- Establish the casualty database
- Train the rehabilitation professionals

Provide community rehabilitation after emergency period
- Provide home visits
- Strengthen the capacity building of village doctors

Early social support ensures that the rehabilitation process is more effective
- Establish a peer support group
- Eliminate physical barriers in the community and family environment through transformation
- Promote cognitive level of community

Enjoy a new life: social support after an emergency
- Support the disabled for livelihood earnings
- Establish village disability association

Comprehensive rehabilitation experience for the earthquake victims of “Intervention of Care” program

In December 2016, “Intervention of Care” program issued “comprehensive rehabilitation • return to the community • social responsibility report of Intervention of Care program”, in which it systematically summarizes the achievements and experiences of “Intervention of Care” program in past eight years, and promotes the practice and experience of the comprehensive rehabilitation of the wounded after the earthquake to other institutions.

1 Handicap International: it is an independent and impartial international aid agency: Upon entering China, it aims to improve the social and economic integration of the handicapped groups, and works closely with local government departments, civil society groups and disability associations to carry out pilot programs; it provides technical support in the “Intervention of Care” program.

2 You & Me Community: it is dedicated to advocating and promoting community rehabilitation strategy in the Chinese mainland: it has been active in the earthquake disaster area since its establishment, helping earthquake victims in Mianzhu, Ya’an and Ludian restore limb function and return to the family and society; it manages and executes the “Intervention of Care” program.

Actively participate in emergency disaster relief

In the face of all kinds of sudden disasters, Sanofi China takes the initiative to give full play to its professional advantages, and encourages employees to participate in disaster relief activities professionally and orderly, so as to form the resultant and positive energy for disaster relief.

After the explosion in Tianjin in August 2015, Sanofi China became the first foreign enterprise to donate to the Red Cross Society of Tianjin. The donation of RMB 1 million was used for the rescue of the wounded in the explosion. Besides, employees of Sanofi China in Tianjin also voluntarily went to the local hospital to provide volunteer service with their medical expertise, which embodies the Sanofi staff’s deep love.

In August 2015, after the Tianjin explosion, Sanofi China donated RMB 1 million

In July 2016, a flood happened in Hubei. Sanofi Pasteur supported the local government to carry out health and epidemic prevention timely after flood. 300 thousand doses of influenza vaccine were urgently donated for disease prevention and control of disaster victims and flood fighting officers and soldiers.

In July 2016, employees spontaneously participated in stamping the donation stamp on the donated vaccine for Wuhan flood.

In July 2016, employees spontaneously participated in stamping the donation stamp on the donated vaccine for Wuhan flood.

In June 2017, a landslide occurred in Maxian, Aba prefecture, Sichuan. Sanofi China, upon understanding the actual needs of the local rescue, donated RMB 300,000 for the rescue of the affected areas.

In November 2017, Sanofi China was awarded the title of “2017 Pioneer Enterprise for Disaster Relief and Rescue” issued by the China Foundation for Poverty Alleviation
The environment in which we live directly affects our health. Sanofi China always strictly controls the effects of drugs, devices and services to human health and the environment in the whole life cycle, pays close attention to environmental footprint in the production and operations, in order to build a healthy, green, vibrant livable ecological environment.
Climate Change and Health

Climate change may have an impact on health. Extreme heat, bad weather and air pollution create favorable conditions for the exacerbation and spread of diseases, thereby threaten public health. Sanofi is committed to addressing issues related to environment and climate change, and continues to carry out research & development for sensitive diseases brought about by some climate changes, and improves the health awareness of stakeholders through volunteer activities in communities.

Reducing Carbon Emissions

In order to reduce the carbon footprint, Sanofi group has developed the 2010-2020 target to reduce carbon emissions: by adopting a responsible way of energy use and improving transportation (product and human) policy, emissions of carbon dioxide produced by the production process directly and by the power consumption are reduced by 20%. Carbon dioxide emissions from logistics in the process of transportation are reduced as well. Sanofi China actively carries out energy saving and emission reduction programs in manufacturing facilities and contributes to the realization of the group’s goals.

Optimizing Energy Use

By continuing to carry out energy saving programs, Sanofi China has effectively been saving resources and reducing the cost of production and operation while actively responding to global climate change. In the past 2015-2016 years, we have carried out dozens of energy saving programs in three manufacturing facilities in Beijing, Hangzhou and Shenzhen.

| Energy Use Optimization of the Three Manufacturing Facilities in Sanofi China |
|-------------------------------|-----------------|-----------------|
| Beijing Pharmaceutical Plant | 344             | 292             |
| Hangzhou Pharmaceutical Plant| 1,598           | 2,261           |
| Shenzhen Vaccine Plant        | 316             | 95              |

Reducing Carbon Emissions in Transportation

From 2015 to 2016, Sanofi China launched three distribution centers. In addition to Xinjiang, Qinghai and Gansu, Sanofi China uses trucks to transport products throughout the country, instead of the original air transport.

In order to further reduce the carbon emissions in the transport of products, more and more cold chain cars are used at Sanofi China instead of cold core boxes to transport drugs and to save cold core boxes. From July 2015 to October 2017, 229,648 cold core boxes were saved in total.

In order to reduce the use of cold core box and reduce the production of wastes, in coming years, Sanofi China will recycle cold core boxes in vaccine transportation to improve the utilization rate of resources.

Facts and Figures:

2015-2016
- the Beijing pharmaceutical plant has completed 6 energy-saving programs
- the Hangzhou pharmaceutical plant has completed 12 energy-saving programs
- the Shenzhen vaccine plant has completed 2 energy-saving programs.

| 2014-2016 Power consumption of ten thousand yuan output value of the three facilities at Sanofi China (megawatt hour / ten thousand yuan) |
|-----------------------------------------------|---------------|---------------|
| Beijing Pharmaceutical Plant                  | 0.031         | 0.013         |
| Hangzhou Pharmaceutical Plant                 | 0.013         | 0.010         |
| Shenzhen Vaccine Plant                         | 0.012         | 0.100         |

| 2014-2016 Carbon emissions of ten thousand yuan output value of the three facilities at Sanofi China (tons / ten thousand yuan) |
|----------------------------------------------------------------------------------|-----------------|-----------------|
| Beijing Pharmaceutical Plant                                                      | 0.012           | 0.012           |
| Hangzhou Pharmaceutical Plant                                                     | 0.002           | 0.001           |
| Shenzhen Vaccine Plant                                                             | 0.151           | 0.080           |

Using Cold Chain Car Instead of Cold Core Box to Transport Medical Products

Source: Center for Disease Control and Prevention (CDC-Atlanta, USA).
Advocating green office

Sanofi China actively advocates energy-saving in the office area, and has carried out a series of activities to promote the staff to start from themselves. For example, we launched a series of posters on energy saving and environmental protection, to remind staff of closing idle appliances and saving office paper; advocated staff to respond positively to the “Earth Hour” activity launched by World Wide Fund for nature (WWF); encouraged employees to put heads together, put forward more and better improvement plans for the further implementation of green office.

RESOURCES RATIONALIZATION MANAGEMENT

Waste disposal

Sanofi China has taken multiple methods to limit the waste generated by the activities. We focus on optimizing product packaging and detergent usage, enhancing the awareness of employees’ handling of food waste, and encouraging effective garbage sorting, recycling and reuse, so as to do our best to reduce the use of additional natural resources. We have launched a waste management program to identify industrial processes and properly deal with different wastes according to the legal requirements.

Sanofi China also uses the self-assessment tool developed by the group to assess the environmental impact of the active ingredients in the waste water, and carries out environmental risk investigation for the water consumption situation of the domestic manufacturing facilities.

Resource rationalization management

Beijing pharmaceutical plant

- 100% compliance treatment of the waste;
- For plastic waste produced for production of injections in plants, the plant staff go to the destruction plant for supervising the destruction before the recycling of plastics;
- Medical waste and laboratory waste liquid are treated by third party qualified companies for innocuous treatment.

Hangzhou pharmaceutical plant

- Hazardous wastes are collected with yellow plastic bags and labeled, which are handled to specialized units for harmless treatment; Health hazard environment audit is conducted every three years for hazardous waste disposal units.
- Non-hazardous waste is reclaimed and disposed by special units.
- After sorting out the living garbage, it is directly collected by the sanitation unit for unified processing.

Shenzhen vaccine plant

- Sorting out the recyclable-class cardboard and other waste for the recycling of the supplier, to reduce the amount of plant waste and avoid entering the municipal waste landfill or incineration system.

Waste disposal measures of the three manufacturing facilities at Sanofi China

<table>
<thead>
<tr>
<th>Year</th>
<th>Beijing pharmaceutical plant</th>
<th>Hangzhou pharmaceutical plant</th>
<th>Shenzhen vaccine plant</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>183</td>
<td>234</td>
<td>330</td>
</tr>
<tr>
<td>2015</td>
<td>287</td>
<td>239</td>
<td>1,740</td>
</tr>
<tr>
<td>2016</td>
<td>278</td>
<td>196</td>
<td>3,130</td>
</tr>
</tbody>
</table>

2014-2016 Harmless waste emission of ten thousand yuan output value of the three facilities at Sanofi China (g / ten thousand yuan)

<table>
<thead>
<tr>
<th>Year</th>
<th>Beijing pharmaceutical plant</th>
<th>Hangzhou pharmaceutical plant</th>
<th>Shenzhen vaccine plant</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>15.09</td>
<td>28.8</td>
<td>1,384.6</td>
</tr>
<tr>
<td>2015</td>
<td>12.31</td>
<td>48.9</td>
<td>201.4</td>
</tr>
<tr>
<td>2016</td>
<td>7.83</td>
<td>38</td>
<td>490.8</td>
</tr>
</tbody>
</table>

2014-2016 Hazardous waste emission of ten thousand yuan output value of the three facilities at Sanofi China (g / ten thousand yuan)

“Protect the earth” environmental protection action

In November 2015, Sanofi China launched the “Planet Mobilization” program of the group. Under the guidance of circular economy, the “Planet Mobilization” program emphasizes the need to take the initiative, and tries to find opportunities to use the wastes in industrial processes, especially some unavoidable wastes, and transforms them into potential resources. By 2025, we expect that the landfill rate of operating waste will have been controlled at 1%, and more than 90% of the residual operating waste will have been recycled.

Water resources management

To alleviate the adverse effects of the growing decline of global freshwater resources on production and life, Sanofi China reduces production water consumption, invites third party agencies to monitor groundwater quality in facilities, and evaluates the water quality of the site where the plant locates through historical data comparison.

Beijing pharmaceutical plant

The renovation of the pollution treatment facilities has been completed; the sewage discharged to the municipal wastewater treatment plant is more stable, and the risk of exceeding the standard discharge is effectively avoided.

Hangzhou pharmaceutical plant

The production sewage is discharged into the regulating pool after the pretreatment in sewage cooling pool, and the domestic sewage is specially treated into clear liquid by removing impurities, degrading, precipitating action and specially treated into clear liquid by removing impurities, degrading, precipitating action and floved to a collection tank, and then discharged into the municipal pipe network.

Shenzhen vaccine plant

They carry out the inspection of the leakage points of the underground water supply network, in order to prevent the leakage of water supply from the city to the pipe and save water.

Water resources management measures of the three manufacturing facilities of Sanofi China

<table>
<thead>
<tr>
<th>Year</th>
<th>Beijing Pharmaceutical Plant</th>
<th>Hangzhou Pharmaceutical Plant</th>
<th>Shenzhen Vaccine Plant</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>0.515</td>
<td>0.058</td>
<td>0.264</td>
</tr>
<tr>
<td>2015</td>
<td>0.062</td>
<td>0.051</td>
<td>0.243</td>
</tr>
<tr>
<td>2016</td>
<td>0.078</td>
<td>0.042</td>
<td>0.476</td>
</tr>
</tbody>
</table>

2014-2016 Water consumption of ten thousand yuan output value of the three facilities at Sanofi China (tons / ten thousand yuan)

<table>
<thead>
<tr>
<th>Year</th>
<th>Beijing Pharmaceutical Plant</th>
<th>Hangzhou Pharmaceutical Plant</th>
<th>Shenzhen Vaccine Plant</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>0.124</td>
<td>0.051</td>
<td>0.051</td>
</tr>
<tr>
<td>2015</td>
<td>0.036</td>
<td>0.046</td>
<td>0.038</td>
</tr>
<tr>
<td>2016</td>
<td>0.044</td>
<td>0.229</td>
<td>0.454</td>
</tr>
</tbody>
</table>

2014-2016 Waste water discharge of ten thousand yuan output value of the three facilities at Sanofi China (tons / ten thousand yuan)
## GRI CONTENT INDEX

<table>
<thead>
<tr>
<th>Disclosure item</th>
<th>Description</th>
<th>Page number</th>
<th>Omission reason</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>GRI 102: General disclosures 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-1</td>
<td>Name of the organization</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-2</td>
<td>Activities, brands, products, and services</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td>102-3</td>
<td>Location of headquarters</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-4</td>
<td>Location of operations</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-5</td>
<td>Ownership and legal form</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-6</td>
<td>Markets served</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-7</td>
<td>Scale of the organization</td>
<td>4-5</td>
<td></td>
</tr>
<tr>
<td>102-8</td>
<td>Information on employee</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>102-9</td>
<td>Supply chain</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>102-10</td>
<td>Significant changes to the organization and its supply chain</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-11</td>
<td>Precautionary Principle or approach</td>
<td>18</td>
<td></td>
</tr>
<tr>
<td>102-12</td>
<td>External initiatives</td>
<td>22-23</td>
<td></td>
</tr>
<tr>
<td>102-13</td>
<td>Membership of associations</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td><strong>Strategy</strong></td>
<td>Speech from the top management</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>Ethics and integrity</strong></td>
<td>Values, principles, standards, and norms of behavior</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Governance</strong></td>
<td>Governance structure</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td><strong>Shareholder engagement</strong></td>
<td>List of stakeholder groups</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>102-41</td>
<td>Collective bargaining agreements</td>
<td>36</td>
<td></td>
</tr>
<tr>
<td>102-42</td>
<td>Identifying and selecting stakeholders</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>102-43</td>
<td>Approach to stakeholder engagement</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>102-44</td>
<td>Appeals and organizational responses of stakeholders</td>
<td>10-11</td>
<td></td>
</tr>
<tr>
<td><strong>Reporting practice</strong></td>
<td>Entities included in the consolidated financial statements</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>102-45</td>
<td>Defining report content and topic boundaries</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>102-46</td>
<td>List of material topicsnever published</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>102-47</td>
<td>Reordering pre-reporting information</td>
<td>3-4</td>
<td></td>
</tr>
<tr>
<td>102-48</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-49</td>
<td>Changes in reporting</td>
<td>The last report disclosed the material issues of the Sanofi Group, and this report disclosed the material issues of Sanofi China</td>
<td></td>
</tr>
<tr>
<td><strong>GRI 204: Procurement practices 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>102-50</td>
<td>Reporting period</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>102-51</td>
<td>Date of most recent report</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>102-52</td>
<td>Reporting cycle</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>102-53</td>
<td>Contact point for questions regarding the report</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>102-54</td>
<td>Claims of reporting in accordance with the GRI Standards</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>102-55</td>
<td>GRI content index</td>
<td>54</td>
<td></td>
</tr>
<tr>
<td>102-56</td>
<td>External assurance</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td><strong>GRI 103: Management approach 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103-1</td>
<td>Explanation of the material topic and its boundary</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>103-2</td>
<td>The management approach and its components</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>103-3</td>
<td>Evaluation of the management approach</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td>204-1</td>
<td>Proportion of spending on local suppliers</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td><strong>GRI 205: Anti-corruption 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103-1</td>
<td>Explanation of the material topic and its boundary</td>
<td>20-21</td>
<td></td>
</tr>
<tr>
<td>103-2</td>
<td>The management approach and its components</td>
<td>20-21</td>
<td></td>
</tr>
<tr>
<td>103-3</td>
<td>Evaluation of the management approach</td>
<td>20-21</td>
<td></td>
</tr>
<tr>
<td>205-2</td>
<td>Transmission and training of anti-corruption policies and procedures</td>
<td>21</td>
<td></td>
</tr>
<tr>
<td><strong>GRI 301: Materials 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103-1</td>
<td>Explanation of the material topic and its boundary</td>
<td>51-52</td>
<td></td>
</tr>
<tr>
<td>103-2</td>
<td>The management approach and its components</td>
<td>51-52</td>
<td></td>
</tr>
<tr>
<td>103-3</td>
<td>Evaluation of the management approach</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>301-3</td>
<td>Reclaimed products and their packaging materials</td>
<td>51</td>
<td>Information is not available - it has not yet been systematically carried out. In the future, the recycling of related materials will be planned for the transport of vaccines.</td>
</tr>
<tr>
<td><strong>GRI 302: Energy 2016</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>103-1</td>
<td>Explanation of the material topic and its boundary</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>103-2</td>
<td>The management approach and its components</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>103-3</td>
<td>Evaluation of the management approach</td>
<td>50-51</td>
<td></td>
</tr>
<tr>
<td>302-1</td>
<td>Energy consumption within the organization</td>
<td>50-51</td>
<td></td>
</tr>
<tr>
<td>302-2</td>
<td>Energy consumption outside the organization</td>
<td>51-52</td>
<td></td>
</tr>
<tr>
<td>302-3</td>
<td>Energy intensity</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>302-4</td>
<td>Reduction of energy consumption</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Disclosure item</td>
<td>Description</td>
<td>Page number</td>
<td>Omission reason</td>
</tr>
<tr>
<td>----------------</td>
<td>-------------</td>
<td>-------------</td>
<td>----------------</td>
</tr>
<tr>
<td>GRI 303: Water 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>303-1 Water withdrawal by source</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>GRI 305: Emissions 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>50-51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>50-51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>50-51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>305-1 Direct (Scope 1) GHG emissions</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>305-2 Energy indirect (Scope 2) GHG emissions</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>305-3 Other indirect (Scope 3) GHG emissions</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td></td>
<td>305-4 GHG emissions intensity</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>GRI 307: Environmental compliance 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>52-53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>52-53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>52-53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>306-1 Water discharge by quality and destination</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>306-2 Waste by type and disposal method</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td>GRI 308: Supplier environmental assessment 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>52</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>51-53</td>
<td></td>
</tr>
<tr>
<td></td>
<td>307-1 Non-compliance with environmental laws and regulations</td>
<td>No violation of the environment, laws and regulations during the reporting period</td>
<td></td>
</tr>
<tr>
<td>GRI 401: Employment 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>36-37</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>401-1 Parental leave</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>GRI 404: Training and education 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>37-38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>37-38</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>36-37</td>
<td></td>
</tr>
<tr>
<td></td>
<td>404-1 Average hours of training per year per employee</td>
<td>No adverse impact in the supply chain on the environment during the reporting period</td>
<td></td>
</tr>
<tr>
<td>GRI 405: Diversity and equal opportunity 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>23</td>
<td></td>
</tr>
<tr>
<td></td>
<td>412-1 Negative social impacts in the supply chain and actions taken</td>
<td>No adverse impact in the supply chain on the environment during the reporting period</td>
<td></td>
</tr>
<tr>
<td>GRI 408: Occupational health and safety 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>39-41</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td></td>
<td>403-2 The proportion of industrial injury categories, industrial injuries, occupational diseases, loss of working time and absence of work, and the number of death in line of duty</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>GRI 409: Customer health and safety 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>16-17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>16-17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>16-17</td>
<td></td>
</tr>
<tr>
<td></td>
<td>416-1 Assessment of the health and safety impacts of product and service categories</td>
<td>100%</td>
<td></td>
</tr>
<tr>
<td>GRI 410: Marketing and advertising 2016</td>
<td>103-1 Explanation of the material topic and its boundary</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-2 The management approach and its components</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>103-3 Evaluation of the management approach</td>
<td>19</td>
<td></td>
</tr>
<tr>
<td></td>
<td>417-1 Requirements for product and services information and labeling</td>
<td>19</td>
<td></td>
</tr>
</tbody>
</table>
Time frame
The information is mainly from January 2015 to December 2016, and some of the information is extended to 2017 or dates back to the previous years.

Release cycle
Sanofi China issued a two-year cycle of social responsibility report, and the last report was published in 2015. This report is the third corporate social responsibility report of Sanofi China.

Scope of reporting
Sanofi’s overall business in China includes Sanofi pharmaceutical operation and vaccine business (Sanofi Pasteur), 11 regional offices and 3 manufacturing facilities. Part of the information comes from the Sanofi group report.

Information sources
The information and data disclosed in this report are derived from the company’s public information, internal documents and related statistical data.

Compilation basis
The report is in line with the “core” program of the GRI standard and is compiled with reference to the social responsibility information disclosure requirements of the Sanofi group.

Anaphora
For convenience, this report uses “we” to refer to “Sanofi China”, and “Sanofi” group” to refer to the “Sanofi group”.

Report acquisition
This report is provided in two ways, printing and electronic version. You can log on to http://www.sanofi.cn to get the electronic version report. If you need to get the printed version report or have questions or suggestions for this report, you can send an e-mail to CSR.China@sanofi.com.

THIRD-PARTY ASSURANCE

Assurance Statement of Corporate Social Responsibility Report

After accepting entrustment from Sanofi (China) Investment Co., Ltd. (hereinafter referred to as “Sanofi (China)”), TUV NORD Asia Pacific Ltd. (hereinafter referred to as TUV NORD) has carried out the third-party assurance on Sanofi (China)'s 2017 Corporate Social Responsibility Report (hereinafter referred to as the "Report"). Sanofi (China) is responsible for collecting, analyzing, summarizing and disclosing the information in the Report. While TUV NORD carries out this work (assurance on the Report) to the extent of its functions and powers set forth in the agreement by and between TUV NORD and Sanofi (China), Sanofi (China) is the user designated by this Statement. This Statement is based on the 2017 Corporate Social Responsibility Report prepared by Sanofi (China). Sanofi (China) is responsible for the completeness and authenticity of the information and data in the Report. This Report, which is the third one publicly issued, invites TUV NORD to independently assure it for the first time.

Scope of assurance
- The key performance and related information of corporate social responsibility during the period from 2015 to 2016 in the Report;
- The assurance is carried out on 19F, Tower 3, Jing'an Kerry Center, Jing'an District, Shanghai, where the headquarters of Sanofi (China) is located. Other branches, manufacturing facilities and regional offices of Sanofi (China) have not been visited;
- To evaluate the management process such as collection, analysis and inspection of data and information involved in the Report;
- In the assurance, the financial data will not be audited repeatedly as they will be assured by a third party. The on-site assurance is carried out on the 6th to the 7th day of November 2017.

Assurance method
The assurance process includes the following activities:
- To review the files provided by Sanofi (China);
- To interview Sanofi (China) individuals who collect information of the Report;
- To access the public information published by relevant website and media, and verify the data and information in the Report through sampling;
- To evaluate the management process such as collection, analysis and inspection of data and information involved in the Report;
- To carry out assurance based on AA1000 Assurance Standard (2008);
- To assure that the events are conducted in accordance with TUV NORD CSR Management Procedures.

Conclusion
Sanofi (China)'s 2017 Corporate Social Responsibility Report prepared by Sanofi (China) has objectively reflected the implementation of its social responsibility and its performance during the period from 2015 to 2016. Through sampling verification, the data in the Report are reliable and objective without any systematic or material errors.
- The overall structure of the Report is complete, while information therein is clear, intelligible and accessible;
- The Report has indicated Sanofi (China)'s implementation of its social responsibility and its performance during the period from 2015 to 2016 from the six parts, i.e. Empower responsibility, Empowering the essence of ethics, Empowering the source of life, Empowering the beauty of human nature, Empowering the light of harmony, and Empowering green vitality, so that the stakeholders can comprehensively understand Sanofi (China)'s development;
Dear readers,

Thank you for reading “2017 Sanofi China Corporate Social Responsibility Report”. We attach great importance to and look forward to hearing from you on the work of Sanofi China corporate social responsibility and this corporate social responsibility report. Your opinions and suggestions are the important basis for us to continuously improve the information disclosure of corporate social responsibility and to promote the management and practice of corporate social responsibility. You can fill in the following form and feed back to us by mail or email. Thank you very much for your valuable advice.

Information feedback table

Name:  
Unit:  
Contact phone:  
Email:  

1. Your assessment of the report:  
□ A Very good  □ B Good  □ C Fair  □ D Poor  

2. Do you think the structure of the report is reasonable?  

3. Can you understand the company’s responsibility concept and practical characteristics through the report?  

4. Do you think the report is easy to read?  

5. Do you think this report is reasonable in content arrangement and layout design?  

6. What is your overall evaluation of the report?  

7. What issues do you pay most attention to? (Multiple choices available)  
□ A Social Responsibility Management  □ B Ethics  □ C Patients  □ D Employees  
□ E Society  □ F the Environment  

8. What is the degree of disclosure of information you are concerned about in the issues?  
□ A Very comprehensive  □ B Comprehensive  □ C Involved to some extent  
□ D Involved rarely  □ E Not involved  

9. Your suggestion to the corporate social responsibility report of Sanofi China:  

You can contact us in the following ways:  
Sanofi (China) Investment Co., Ltd.  
Address: 19F, Tower 3, Jing'an Kerry Center, No. 1228, Middle Yan’an Road, Jing’an District, Shanghai  
Zip code: 200040 Telephone: 86-21-22266666  Email: CSR.China@sanofi.com

READER FEEDBACK

Suggestions for improvement

We make the following suggestions through assurance and evaluation for improving Sanofi (China)’s practice and management of its social responsibility:

- It is suggested to disclose the deficiencies in the implementation of corporate social responsibility and improvement plans for better balance of the Report;
- It is suggested to organically combine the GRI Standards with KPI evaluation on each department to make the social responsibility management more high-efficiency;
- It is suggested to strengthen the disclosure of information related to the medical information communication representatives.

Special statements:

This Statement excludes:

- Activities beyond the information disclosure;
- Statement on Sanofi (China)’s standpoints, viewpoints, belief, objective, future direction of development, and commitment.

Statement on independence and capacity

TUV NORD Group, as a certification organization leading in the world, sets up branches in more than 70 countries all over the world, and provides inspection, test and verification services, including certification of management system and products, audit and training on quality, environment, society and morality, and assurance on environment, social responsibility and sustainable development report. As one of the branches of TUV NORD Group, TUV NORD Asia Pacific Ltd. is independent and free from any interests conflicting with Sanofi (China) Investment Co., Ltd. or its branches and stakeholders during assurance on this Corporate Social Responsibility Report. All the information herein is provided by Sanofi (China), while TUV NORD does not participate in the preparation of the Report.

TUV NORD Asia Pacific Ltd.

Authorized representative: Song Haining  
Assurance Group Leader: Huang Li  
Date: November 28, 2017  

Notes: The Chinese version of this Statement shall prevail in case of any disparity with the English version.

Authorized representative:  
Date: November 28, 2017